000 01288 a2200373 4500
005 20250515124936.0
264 0 _c20090205
008 200902s 0 0 eng d
022 _a0724-8741
024 7 _a10.1007/s11095-008-9641-0
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLarsen, Anne
245 0 0 _aLipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis.
_h[electronic resource]
260 _bPharmaceutical research
_cDec 2008
300 _a2769-77 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAnimals
650 0 4 _aBiological Availability
650 0 4 _aChemistry, Pharmaceutical
650 0 4 _aDanazol
_xadministration & dosage
650 0 4 _aLipolysis
650 0 4 _aMale
650 0 4 _aPharmaceutical Vehicles
650 0 4 _aRats
650 0 4 _aRats, Sprague-Dawley
650 0 4 _aSolubility
650 0 4 _aSurface-Active Agents
_xchemistry
650 0 4 _aSuspensions
700 1 _aHolm, René
700 1 _aPedersen, Mette Lund
700 1 _aMüllertz, Anette
773 0 _tPharmaceutical research
_gvol. 25
_gno. 12
_gp. 2769-77
856 4 0 _uhttps://doi.org/10.1007/s11095-008-9641-0
_zAvailable from publisher's website
999 _c18075329
_d18075329